GAMCO Investors’s Myriad Genetics MYGN Stock Holding History

GAMCO Investors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-25,000	Closed	-$765K	–	816
2016 Q2	$765K	Hold	25,000	–	–	0.01%	637
2016 Q1	$936K	Hold	25,000	–	–	0.01%	594
2015 Q4	$1.08M	Hold	25,000	–	–	0.01%	590
2015 Q3	$937K	Hold	25,000	–	–	0.01%	616
2015 Q2	$850K	Hold	25,000	–	–	﹤0.01%	639
2015 Q1	$885K	Buy	+25,000	New	+$895K	﹤0.01%	646

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GAMCO Investors's MYGN Position: Q3 2016 in Review

GAMCO Investors sold out of Myriad Genetics (MYGN) in Q3 2016, closing a stake of 25,000 shares — an estimated $765K sold.

GAMCO Investors first reported a position in MYGN in Q1 2015 and held it in 6 quarters. The position peaked at $1.08M in Q4 2015. 223 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

GAMCO Investors reported no remaining Myriad Genetics position as of Q3 2016 after selling out during the quarter.
GAMCO Investors sold 25,000 Myriad Genetics shares in Q3 2016, an estimated $765K.
GAMCO Investors first reported a position in Myriad Genetics in Q1 2015 and held it in 6 quarters.
GAMCO Investors's Myriad Genetics position peaked at $1.08M in Q4 2015.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on GAMCO Investors's 13F filing for Q3 2016, filed 14 Nov 2016.